Back to top
more

BioMarin Pharmaceutical (BMRN)

(Real Time Quote from BATS)

$85.60 USD

85.60
317,379

+1.51 (1.80%)

Updated Jul 22, 2024 01:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Why BioMarin (BMRN) Could Beat Earnings Estimates Again

by Zacks Equity Research

BioMarin (BMRN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

CHMP Endorses BioMarin's (BMRN) Voxzogo for Use in Infants

by Zacks Equity Research

A final decision study on BioMarin's (BMRN) Voxzogo to treat children above four months with achondroplasia is expected before year's end.

Why Is Seattle Genetics (SGEN) Up 6.5% Since Last Earnings Report?

by Zacks Equity Research

Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Incyte (INCY) Down 0.7% Since Last Earnings Report?

by Zacks Equity Research

Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

BioMarin (BMRN) Q2 Earnings & Sales Top, Voxzogo Drives Sales

by Zacks Equity Research

BioMarin (BMRN) beats on earnings and sales estimates in the second quarter on the back of robust demand for Voxzogo.

BioMarin (BMRN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

Although the revenue and EPS for BioMarin (BMRN) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

BioMarin Pharmaceutical (BMRN) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

BioMarin (BMRN) delivered earnings and revenue surprises of 14.89% and 0.65%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Biotech Stock Roundup: BMRN's Gene Therapy Gets Approval, SGTX Up on Buyout by LLY

by Zacks Equity Research

Regulatory and acquisition updates from BioMarin (BMRN) and Sigilon (SGTX) are in focus in the biotech sector.

BioMarin (BMRN) Gets FDA Nod for Hemophilia A Gene Therapy

by Zacks Equity Research

Following FDA's approval, BioMarin's (BMRN) Roctavian becomes the first gene therapy for treating severe hemophilia A.

Pfizer (PFE) Posts Upbeat Data From Hemophilia Drug Study

by Zacks Equity Research

Data from a late-stage study shows that treatment with Pfizer's (PFE) experimental anti-TFPI inhibitor led to a significant reduction in annualized bleeding rate in hemophilia A and B patients.

Why Is BioMarin (BMRN) Down 4% Since Last Earnings Report?

by Zacks Equity Research

BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

PTC Therapeutics' (PTCT) PKU Drug Meets Study Goal, Up 7.6%

by Zacks Equity Research

Data from a late-stage study data shows that treatment with PTC Therapeutics' (PTCT) sepiapterin led to a significant reduction in Phe levels in PKU patients. Post the news, share price rises.

New Strong Sell Stocks for May 1st

by Zacks Equity Research

AOMR, BMRN and CUTR have been added to the Zacks Rank #5 (Strong Sell) List on May 1, 2023.

BioMarin (BMRN) Q1 Earnings Top, Voxzogo Drives Sales

by Zacks Equity Research

BioMarin (BMRN) reports encouraging first-quarter results, wherein both earnings and sales beat estimates. The rapid uptake of Voxzogo boosts revenues.

BioMarin (BMRN) Reports Q1 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

While the top- and bottom-line numbers for BioMarin (BMRN) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

BioMarin Pharmaceutical (BMRN) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

BioMarin (BMRN) delivered earnings and revenue surprises of 39.53% and 4.17%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for PBE

Arcturus Therapeutics (ARCT) Beats Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 332.80% and 19.14%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

BridgeBio Pharma (BBIO) Surges 77% YTD: Here's Why

by Zacks Equity Research

Shares of BridgeBio (BBIO) are up rising since the company announced positive data from a mid-stage study, which evaluated its experimental drug infigratinib in children with achondroplasia, a form of dwarfism.

Should Schwab U.S. Mid-Cap ETF (SCHM) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for SCHM

Biotech Stock Roundup: PTGX Gains on Study Data, BMRN Faces Setback & More

by Zacks Equity Research

Pipeline and regulatory updates from Protagonist (PTGX) and BioMarin (BMRN) are the key highlights from the biotech sector during the past week.

BioMarin (BMRN) Provides FDA Filing Update for Gene Therapies

by Zacks Equity Research

The FDA accepts BioMarin's (BMRN) label-expansion filing for Voxzogo to treat children under five years with achondroplasia. The agency extends the review period for Roctavian BLA.

Is the Options Market Predicting a Spike in BioMarin Pharmaceutical (BMRN) Stock?

by Zacks Equity Research

Investors need to pay close attention to BioMarin Pharmaceutical (BMRN) stock based on the movements in the options market lately.

BioMarin (BMRN) Q4 Earnings Miss, Sales Beat, Stock Down

by Zacks Equity Research

BioMarin (BMRN) reports mixed Q4 results as it misses estimates for earnings but beats the same for sales. Its 2023 sales guidance falls short slightly

Compared to Estimates, BioMarin (BMRN) Q4 Earnings: A Look at Key Metrics

by Zacks Equity Research

The headline numbers for BioMarin (BMRN) give insight into how the company performed in the quarter ended December 2022, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.